Dan Rhodes

Dan Rhodes is a scientist and entrepreneur focused on precision medicine in oncology. He is the co-founder and CEO of Strata Oncology, a venture-backed precision oncology company committed to accelerating the impact of precision medicine for patients with cancer.

From 2012-2015, Dan was Vice President of Oncology for Thermo Fisher Scientific (Life Technologies) where he oversaw the development of cancer sequencing products and pharma companion diagnostic partnerships.

From 2006-2012, Dan was co-founder and CEO of Compendia Bioscience, a University of Michigan spin-off formed to further develop and commercialize his thesis project, Oncomine, a cancer genome data-mining platform. Over six years, Compendia grew to 20+ pharma customers, 10,000+ users and nearly $10M in annual revenue, culminating in the acquisition by Life Technologies in 2012.

He has co-authored 40+ publications and is a co-inventor on 10 patents, including the discovery of gene fusions as a genetic cause of prostate cancer. He has received the Weintraub Award, a national recognition for excellence in graduate studies, the AACR Team Science Award, was a Crain’s Detroit Mergers and Acquisitions Deal of the Year Finalist, received the Michigan Venture Capital Association’s “Up and Coming Company of the Year” Award and in 2019, Dan was named Ernst & Young Entrepreneur of the Year for the Midwest region. Dan served on the oversight committee for the Michigan Translational Research and Commercialization (MTRAC) Program and on the Advisory Boards for eLab Ventures and the Monroe-Brown Biomedical Seed Fund.

Dan received both a Bachelor of Science in Molecular Biology and a Doctorate in Bioinformatics from The University of Michigan.